Lixisenatide (Leu-13C6,15N) TFA
Description
Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer’s disease and atherosclerosis.
Product Information
| Product Name | Lixisenatide (Leu-13C6,15N) TFA |
| Molecular Weight | 4879.47 (free base) |
| Formula | C21013C6H349N6015NO65S.xC2HF3O2 ?DZ?? CAS 320367-13-3 |
| Sequence | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-{Leu-13C6,15N}-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2 |
| Sequence Shortening | HGEGTFTSD-{Leu-13C6,15N}-SKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2 |
